It is planned to vaccinate about 4,000 expectant mothers at 22-24 weeks of pregnancy. The trials will be held in the U.S., Argentina, Brazil, Canada, Chile, Mozambique, South Africa, Spain and the UK.
Meanwhile, the company stated that some participants will get the vaccine during the trials and some will get a placebo. The researchers will study any negative side effects for women, including miscarriage.
“We are proud to start this study in pregnant women and continue to gather the evidence on safety and efficacy to potentially support the use of the vaccine by important subpopulations," Pfizer representative Dr. William Gruber said.
As we reported, Pfizer became the fourth company that filed its appeal to register its vaccine against coronavirus in Ukraine. Currently, there are also registration appeals from Sinovac Life Sciences company (China) and Serum Institute of India.